Membranoproliferative glomerulonephritis secondary to chronic myeloid leukemia.
The nephrotic syndrome (NS) is a well documented complication of hematological malignancies. However, chronic myeloid leukemia (CML) is rarely complicated by the NS, and it occurs usually after allogenic stem cell transplantation or interferon alpha therapy for CML. The NS as a complication of untreated CML is also rare. We report a 31-year-old patient who presented with features of The NS. He was diagnosed to have CML one year ago and was on irregular treatment with imatinib mesylate. The renal biopsy and immunofluorescence revealed membrano-proliferative glomerulonephritis type I. The patient was retreated with imatinib mesylate and the NS resolved gradually over three months. This maybe the third case in literature of membrano-proliferative glomerulonephritis associated with CML.
Subramanian
Murali
M
Department of Medical Oncology, M.S. Ramaiah Medical College, Bangalore, India. muralisubramanian@gmail.com
Kilara
Nalini
N
Manjunath
R
R
Mysorekar
Vijaya
V
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D004232:Diuretics / Q000627:therapeutic use; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy; D008297:Male; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D004232:Diuretics; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate